Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Non-Current Debt (2022 - 2026)

Kura Oncology has reported Non-Current Debt over the past 5 years, most recently at $9.7 million for Q1 2026.

  • Quarterly Non-Current Debt rose 27.44% to $9.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $9.7 million through Mar 2026, up 27.44% year-over-year, with the annual reading at $9.7 million for FY2025, 40.41% up from the prior year.
  • Non-Current Debt was $9.7 million for Q1 2026 at Kura Oncology, roughly flat from $9.7 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $9.7 million in Q1 2026 and troughed at $5.3 million in Q3 2025.
  • The 5-year median for Non-Current Debt is $9.2 million (2022), against an average of $8.4 million.
  • The largest YoY upside for Non-Current Debt was 40.41% in 2025 against a maximum downside of 31.21% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $9.2 million in 2022, then rose by 1.9% to $9.3 million in 2023, then fell by 25.89% to $6.9 million in 2024, then skyrocketed by 40.41% to $9.7 million in 2025, then rose by 0.39% to $9.7 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Non-Current Debt are $9.7 million (Q1 2026), $9.7 million (Q4 2025), and $5.3 million (Q3 2025).